Keshen Qu

Keshen Qu

Auto-generated profile, based on publicly available information

Keshen Qu

Department of Dermatology, Shaanxi Hospital of Traditional Chinese Medicine, Xi’an, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2019 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
KQKe Shen Qu
Ke Shen Qu
YLYang Li
Yang Li
YLYue Liang
Yue Liang
XHXiao Jie Hu
Xiao Jie Hu
XWXuan Yu Wang
Xuan Yu Wang
HQHuafa Que
Huafa Que
Background. Diabetic foot ulcer (DFU) is one of the most common complications of diabetes mellitus, with the wound not healing as expected and healing slowly. Poor control can develop into gangrene and even amputation. Currently, the existing treatments are not satisfactory enough. In China, KangFuXin liquid (KFXL) has been clinically used to treat DFU and has shown good clinical efficacy. In order to provide more reference to clinicians and experts, evidence of efficacy for it needs to be further rigorously evaluated. Methods. Eight electronic databases were searched to identify eligible randomized clinical trials (RCTs) published from construction of the library to April 2019. There is no language or data restriction; 11 trials involving 889 participants met the inclusion criteria. These RCTs compared the total effective rate, cure rate, cure time, and adverse events associated with KFXL. The Cochrane Handbook guidelines were used to assess the risk of bias and to evaluate the methodological quality of eligible studies. The methodological quality of included studies was generally low. Dichotomous and continuous data were presented using risk ratios (RRs) and mean differences (MDs), respectively. Results. Compared with the basic treatment, meta-analyses showed that KFXL combined with basic treatment can improve the total effective rate (RR = 1.38; 95% CI = 1.23–1.54; P<0.00001; fixed effect model: I2 = 32%) and cure rate (RR = 1.67; 95% CI = 1.17–2.38; P=0.005; random effect model: I2 = 65%), and shorten the healing time (MD = −5.73; 95% CI = −6.95 to −4.52; P<0.00001; random effect model). Moreover, under the same basic treatment, KFXL had a better effect than external use of pharmaceutical medications (RR = 1.95; 95% CI = 1.30–2.93; P=0.001), but the cure rate was not significantly different. Also, KFXL had nothing to do with adverse reactions. Conclusion. The evidence confirms that KFXL is an effective treatment for DFU. However, further large-scale, rigorously designed trials and high-quality studies are needed to confirm the role of KFXL in the treatment of DFU.

10 February 2023 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
KQKe-Shen Qu
Ke-Shen Qu
YRYi Ru
Yi Ru
DYDan Yang
Dan Yang
KLKuai Le
Kuai Le
YLYing Luo
Ying Luo
HQHuafa Que
Huafa Que

1 June 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
KQKe-Shen Qu
Ke-Shen Qu
YLYing Luo
Ying Luo
XYXiaoning Yan
Xiaoning Yan
KLKuai Le
Kuai Le
YRYi Ru
Yi Ru
MXMeng Xing
Meng Xing

6 March 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MXMeng Xing
Meng Xing
XYXiaoning Yan
Xiaoning Yan
JGJiangtao Guo
Jiangtao Guo
WLWenbin Li
Wenbin Li
ZLZhangJun Li
ZhangJun Li
YLYing Luo
Ying Luo
Introduction: Oral Banzhilian formula (BZLF) is effective in the clinical treatment of psoriasis. However, the effectiveness and mechanism of different drug delivery routes deserve further study.Methods: First, we established the mouse model of psoriasis using imiquimod (IMQ), and high-performance liquid chromatography (HPLC) was used for the quality control of BZLF. Secondly, Total RNA Sequencing and bioinformatics analysis were used to explore the regulatory mechanism of BZLF in improving psoriatic lesions. Finally, further verification was based on animal experiments.Results: we externally applied BZLF for skin lesions in an imiquimod-induced psoriasis mouse model and found that BZLF alleviated psoriasis-like skin lesions while inhibiting the expression of Ki67 and inflammatory factors (Il17a, Tnf-α, S100a7 and Cxcl1) in skin lesions. Transcriptome sequencing results suggested that BZLF inhibited signalling pathways closely related to psoriatic inflammation, such as the IL-17 signalling pathway, chemokine signalling pathway, TNF signalling pathway, and NF-kappa B signalling pathway, and the protein-protein interaction (PPI) network identified LCN2 as one of the core target genes and screened out its regulated downstream gene MMP9.Discussion: Our findings suggest that the anti-psoriatic mechanism of BZLF involved in downregulating the LCN2/MMP-9 axis.